Vasopeptidase inhibition and endothelial function in hypertension.
Vasopeptidase inhibitors are a new class of drugs capable of inhibiting both angiotensin-converting enzyme and neutral endopeptidase 24.11. This involves simultaneous inhibition with a single molecule of two key enzymes, ACE and NEP, which are both involved in the regulation of cardiovascular homeostasis in many ways. This includes metabolism of several vasoactive peptides and their clearance from the circulation, therefore contributing to neurohumoral modulation, which might have therapeutic advantages in the prevention of endothelial dysfunction in hypertension.
d'Uscio
L V
LV
Department of Anesthesiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. dUscio.Livius@mayo.edu
Lüscher
T F
TF
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D009320:Atrial Natriuretic Factor / Q000502:physiology*; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000378:metabolism; D016232:Endothelins / Q000502:physiology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D015260:Neprilysin / Q000037:antagonists & inhibitors* / Q000502:physiology; D009569:Nitric Oxide / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D017466:Receptors, Endothelin / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D016232:Endothelins; D017466:Receptors, Endothelin; D009569:Nitric Oxide; D009320:Atrial Natriuretic Factor; D019001:Nitric Oxide Synthase; D015260:Neprilysin; D001920:Bradykinin